Dr John Schneekloth
Dr Michal Minczuk
Dr Pawel Sledz
Dr Pawel Sledz is interested in structure-based development of small molecules to combat cancer, in particular targeting proteins involved in epitranscriptomic and epigenetic regulation. Postranscriptional modifications of RNA constitute a novel and very exciting opportunity for drug discovery, particularly in oncology. His team pioneered structural and chemical biology studies of m6A-modification machinery, and leveraged on these findings to develop chemical probes targeting m6A-relevant protein targets (protein-RNA interactions and RNA-modifying proteins), active in the cellular models of cancer.
Professor François Fuks
Dr Barak Akabayov
Whitney Zhao
Emmy Koeleman
Simon Lewis
Simon Lewis has worked in technology innovation for over 30 years. Currently Director of Product for PitPat – the activity monitor for dogs – he’s previously invented, developed and marketed many technologies that have changed the lives of human users. An engineer by training, but a student of human behaviour by practice, he lives in the stormy intersection of those two worlds, and tries to smooth the waves he finds there.
